Diabetologia: In diet-induced obese mice, glucose intake in skeletal muscle was stimulated with hydroxymythyl dihydroxydone epinephrine-induced agonists to improve glucose stabilization, insulin resistance, and liver fat degeneration

In contrast to acute treatment, chronic stimulation of epinephrine-stimulating mediators has been reported to reduce blood sugar levels in diabetic model mice and improve glucose and insulin tolerance, although the mechanism is unclear.
researchers recently described a new approach by stimulating glucose intake in skeletal muscle cells by stimulating 2-adrenaline-mediated.
study, the researchers further explored the potential therapeutic correlation of stimulating epinephrine-stimulating bodies to improve glucose stability, as well as their mechanisms of action.
lead to obesity in C57Bl/6N mice through diet and were given a wide range of doses and treatment time of Clenbuterlo hydrochloride within 42 days.
glucose stability was determined by sugar tolerance test.
researchers also measured glucose intake in skeletal muscles, insulin sensitivity in insulin tolerance tests, plasma insulin levels, liver lipids, and glycogen.
with previous findings, acute clenbuterero increases blood sugar and insulin levels.
However, after 4 days of treatment, the beneficial effects of Clenbuterio hydrochloride have been shown in glucose stability (glucose tolerance improved by 32%, p.lt; 0.01 after 4 days), and these effects continued for 42 days.
these beneficial metabolic effects can be achieved by low doses of 0.025 mg kg - 1 day - 1 (40 times lower than previously studied).
it is worth noting that long-term low-dose bichloroolamine therapy improved systemic insulin sensitivity (glucose insulin post-injection disposal rate increased by 1.38±0.31% / minute compared to 0.15 / minute control mice ±0.36%, p slt; 0.05), significantly reducing liver fat degeneration (40%, p.lt; 0.01) and glycogen (23%, p, 0.05).
glucose resistance was improved after 4 days of treatment, and these effects were maintained for 42 days.
dose in the clinically relevant microgram range achieved results.
In theory, long-term low-dose Clenbuterrote therapy improves glucose stability in insulin-resistant mice, most likely by stimulating skeletal glucose intake and improving systemic insulin sensitivity, as well as by reducing liver lipids and glycogen.
, selective acetyl methyl-2 epinephrine-energy astrists may be an attractive potential treatment for type 2 diabetes.
this has yet to be confirmed in humans.
。